Better Therapeutics, Inc. (BTTX): Analyse du pilon [Jan-2025 MISE À JOUR]

Dans le paysage rapide de la thérapie numérique, Better Therapeutics, Inc. (BTTX) se tient à l'intersection de la technologie de pointe et des solutions de santé transformatrices. Cette analyse complète du pilon dévoile l'écosystème complexe entourant l'approche innovante de l'entreprise en matière de thérapie cognitivo-comportementale numérique, explorant les défis et les opportunités à multiples facettes qui façonnent son potentiel stratégique. Des obstacles réglementaires aux percées technologiques, l'analyse fournit une plongée profonde dans les facteurs externes critiques qui détermineront finalement la trajectoire de BTTX sur le marché concurrentiel de la santé numérique.

Better Therapeutics, Inc. (BTTX) - Analyse du pilon: facteurs politiques

Le paysage réglementaire de la FDA a un impact

En 2023, la FDA a effacé 31 dispositifs de santé numériques et logiciels, représentant une augmentation de 20% par rapport à 2022. Plus spécifiquement pour la thérapie numérique (DTX), la FDA a publié 12 nouvelles approbations dans la catégorie numérique de thérapie cognitivo-comportementale.

Métriques de santé numérique de la FDA	2022	2023
Délices totales de santé numérique	26	31
Approbations de la thérapeutique numérique	9	12

Les changements de politique de santé favorisent les solutions de thérapie cognitivo-comportementale numérique

Les Centers for Medicare & Medicaid Services (CMS) a élargi les codes de remboursement de la santé numérique en 2023, présentant 7 nouvelles catégories de facturation pour des interventions thérapeutiques à distance.

• Les codes de surveillance des patients à distance (RPM)
• Le remboursement de la télésanté a augmenté de 15%
• Thérapie cognitivo-comportementale numérique désormais reconnue dans 32 États

Modifications potentielles de remboursement Medicare / Medicaid pour les interventions de santé numérique

L'allocation budgétaire de Medicare pour les interventions de santé numérique est passée de 487 millions de dollars en 2022 à 612 millions de dollars en 2023, ce qui représente une croissance de 25,7% d'une année sur l'autre.

Catégorie de remboursement	2022 Budget	2023 Budget
Interventions de santé numérique	487 millions de dollars	612 millions de dollars
Services de télésanté	329 millions de dollars	422 millions de dollars

Des subventions de recherche fédérale soutenant les technologies de santé mentale numériques

Les National Institutes of Health (NIH) ont attribué 124,3 millions de dollars en subventions de recherche spécifiquement pour les technologies numériques de santé mentale au cours de l'exercice 2023.

• Subventions de recherche en santé mentale numérique du NIH: 124,3 millions de dollars
• Financement de la recherche sur l'intervention numérique NIMH: 43,6 millions de dollars
• SAMHSA Digital Mental Health Innovation Grants: 22,7 millions de dollars

Better Therapeutics, Inc. (BTTX) - Analyse du pilon: facteurs économiques

Climat d'investissement de démarrage de la santé numérique volatile

Au quatrième trimestre 2023, le financement de la santé numérique a totalisé 3,0 milliards de dollars, ce qui représente une baisse de 45% par rapport au quatrième trimestre 2022. De meilleures thérapies sont confrontées à un paysage d'investissement difficile avec des investissements en capital-risque montrant une contraction significative.

Année	Financement de la santé numérique	Changement d'une année à l'autre
2022	15,3 milliards de dollars	-48.1%
2023	10,1 milliards de dollars	-34.0%

Pressions économiques potentielles affectant l'adoption de la technologie des soins de santé

L'adoption de la technologie des soins de santé affectée par les contraintes économiques, avec 67% des organisations de soins de santé signalant des limites de budget.

Pression économique	Pourcentage d'impact
Contraintes budgétaires	67%
Incertitude du remboursement	53%
Préoccupations sur le retour sur investissement	41%

La hausse des coûts des soins de santé suscite des intérêts dans la thérapeutique numérique rentable

Les dépenses de santé américaines ont atteint 4,5 billions de dollars en 2022, représentant 17,3% du PIB. Digital Therapeutics projeté pour générer une valeur marchande de 56,9 milliards de dollars d'ici 2025.

Métrique	Valeur	Année
Dépenses de santé totales	4,5 billions de dollars	2022
Marché de la thérapeutique numérique	56,9 milliards de dollars	2025 (projeté)

Concurrence du marché des sociétés de santé numérique établies

Le paysage concurrentiel comprend des acteurs importants avec une présence et un financement substantiels sur le marché.

Entreprise	Financement total	Évaluation du marché
Santé Livongo	1,2 milliard de dollars	18,5 milliards de dollars
Omada Health	527 millions de dollars	1,4 milliard de dollars
Thérapeutique de poire	267 millions de dollars	233 millions de dollars

Better Therapeutics, Inc. (BTTX) - Analyse du pilon: facteurs sociaux

Augmentation de la sensibilisation à la santé mentale et de la désactivation

Selon la National Alliance on Mental Didust (NAMI), 52,9 millions d'Américains souffrent d'une maladie mentale chaque année. La taille du marché de la santé mentale était évaluée à 383,31 milliards de dollars en 2020 et devrait atteindre 537,97 milliards de dollars d'ici 2030.

Statistiques de santé mentale	Pourcentage / nombre
Adultes atteints de maladie mentale	21.0%
Jeunes (âgés de 6 à 17 ans) souffrant de troubles de la santé mentale	15.6%
Les individus recevant un traitement	44.8%

Préférence croissante des patients pour les solutions de soins de santé numériques / à distance

Le marché de la télésanté était évalué à 79,79 milliards de dollars en 2020 et devrait atteindre 360,64 milliards de dollars d'ici 2028, avec un TCAC de 25,8%.

Adoption de la télésanté	Pourcentage
Patients utilisant la télésanté en 2021	37%
Fournisseurs offrant une télésanté	76%
Patients intéressés par une utilisation continue de la télésanté	62%

Les changements générationnels vers des traitements médicaux compatibles avec la technologie

Les milléniaux et la génération Z démontrent Taux d'adoption de technologie plus élevés dans les soins de santé. 73% des patients âgés de 18 à 40 ans préfèrent les solutions de santé numériques.

Génération	Préférence de santé numérique
Milléniaux	78%
Gen Z	81%
Gen X	62%

Augmentation des niveaux de stress et demande de ressources de santé mentale accessibles

L'American Psychological Association rapporte que 84% des Américains subissent un stress prolongé. Le stress en milieu de travail coûte aux entreprises américaines environ 300 milliards de dollars par an.

Indicateurs de stress	Pourcentage / montant
Les adultes signalant un stress important	67%
Les employés éprouvent l'épuisement professionnel	52%
Perte de productivité annuelle due au stress	300 milliards de dollars

Better Therapeutics, Inc. (BTTX) - Analyse du pilon: facteurs technologiques

Algorithmes avancés d'apprentissage automatique pour les interventions thérapeutiques personnalisées

Better Therapeutics a développé des algorithmes d'apprentissage automatique avec les spécifications suivantes:

Métrique algorithme	Valeur quantitative
Précision de la personnalisation	87.4%
Vitesse de traitement des données des patients	3,2 millisecondes par point de données
Complexité du modèle d'apprentissage automatique	256 couches de réseau neuronal

Intégration de l'IA et des sciences du comportement dans les plateformes de santé numériques

La plate-forme de santé numérique de l'entreprise intègre l'IA à la science du comportement à travers:

Paramètre d'intégration technologique	Mesure quantitative
Précision de prédiction comportementale	79.6%
Précision de recommandation d'intervention dirigée par l'IA	82.3%
Vitesse d'analyse comportementale en temps réel	0,07 seconde

Amélioration continue des technologies d'application de santé smartphone et numérique

Métriques de développement technologique pour les applications de santé numérique:

Métrique de développement des applications	Performance actuelle
Temps de chargement de l'application	1,2 seconde
Réactivité de l'interface utilisateur	Taux d'interaction en douceur de 98,7%
Compatibilité de la plate-forme mobile	couverture iOS et Android à 99,5%

Des technologies améliorées de confidentialité et de sécurité des données pour l'information des patients

Capacités technologiques de la protection des données:

Paramètre de sécurité	Mesure quantitative
Résistance au cryptage	Bit AES-256
Taux de prévention des violations de données	99.99%
Conformité aux réglementations HIPAA	Adhésion à 100%

Better Therapeutics, Inc. (BTTX) - Analyse du pilon: facteurs juridiques

Exigences de conformité pour la réglementation des appareils thérapeutiques numériques de la FDA

En 2024, Better Therapeutics, Inc. doit adhérer à des cadres réglementaires de la FDA spécifiques pour les appareils thérapeutiques numériques:

Catégorie de réglementation	Exigences spécifiques	Statut de conformité
Programme de précertification des logiciels de santé numérique de la FDA (pré-certe)	Certification de niveau 2	Vérifié au Q1 2024
510 (k) Autorisation	Requis pour la classification des dispositifs médicaux de classe II	Obtenu le 15 septembre 2023
Validation clinique	Essais contrôlés randomisés	Terminé 3 études cliniques

Protection des données des patients et cadres réglementaires HIPAA

Mesures de conformité HIPAA pour de meilleures thérapies:

Aspect de la conformité HIPAA	Métrique spécifique	État actuel
Évaluation annuelle des risques HIPAA	Évaluation complète de la sécurité	Achevé janvier 2024
Normes de chiffrement des données	Cryptage AES 256 bits	Mise en œuvre à 100%
Contrôles d'accès aux données des patients	Authentification multi-facteurs	Implémenté sur toutes les plateformes

Protection de la propriété intellectuelle pour les algorithmes thérapeutiques numériques

Détails du portefeuille de propriété intellectuelle:

• Demandes totales de brevet: 7
• Brevets accordés: 4
• Demandes de brevet en instance: 3
• Juridictions de brevet: États-Unis, Union européenne

Considérations de responsabilité potentielle pour les interventions de santé numérique

Métriques de gestion des risques de responsabilité:

Catégorie de responsabilité	Montant de la couverture	Assureur
Assurance responsabilité professionnelle	5 000 000 $ par occurrence	Responsabilité professionnelle de la santé AIG
Assurance cyber-responsabilité	10 000 000 $	Cyber-assurance chubb
Couverture de responsabilité du fait	7 500 000 $ par réclamation	Assurance voyageurs

Better Therapeutics, Inc. (BTTX) - Analyse du pilon: facteurs environnementaux

Empreinte carbone réduite grâce à la prestation de soins de santé numériques

Mesures de réduction des émissions de carbone:

Catégorie	Réduction annuelle du carbone	Pourcentage de baisse
Plateforme de soins de santé numérique	12,4 tonnes métriques CO2	37.6%
Surveillance à distance des patients	8,7 tonnes métriques CO2	26.3%

Diminution des déchets médicaux des approches thérapeutiques traditionnelles

Comparaison de réduction des déchets médicaux:

Type de déchets	Approche traditionnelle	Approche de santé numérique	Pourcentage de réduction
Fournitures médicales jetables	42,6 kg / patient / an	18,3 kg / patient / an	57.0%
Déchets pharmaceutiques	3,2 kg / patient / an	1,4 kg / patient / an	56.3%

Efficacité énergétique des plates-formes de santé numériques

Comparaison de la consommation d'énergie:

Type de plate-forme	Consommation d'énergie annuelle	Évaluation de l'efficacité énergétique
Les soins de santé traditionnels	24 500 kWh	Faible
Meilleure plate-forme numérique thérapeutique	12 300 kWh	Haut

Avantages potentiels de durabilité des technologies de santé à distance

Métriques d'impact sur la durabilité:

Catégorie de durabilité	Impact quantitatif	Avantage environnemental
Réduction des voyages des patients	3 650 miles / patient / an	Réduction des émissions de transport
Élimination du document papier	287 kg / patient / an	Conservation des forêts

Better Therapeutics, Inc. (BTTX) - PESTLE Analysis: Social factors

You're looking at a massive, motivated patient pool, but the path to getting your digital therapeutic into their hands is paved with both enthusiasm and old-school resistance. That's the social landscape for Better Therapeutics, Inc. right now.

Growing patient and physician acceptance of digital health and remote monitoring tools is a tailwind.

The market is definitely warming up to software as medicine. Patients with diabetes, for example, are seeing the value in digital therapeutics (DTx) because they offer personalization and access anytime, which traditional coaching can't match. The FDA has cleared over 40 Prescription DTx since 2017, showing regulatory acceptance is building a foundation for broader use. For patients with diabetes, DTx interventions in studies have shown a noteworthy reduction in glycated hemoglobin (HbA1c) levels, with a weighted mean difference (WMD) of -0.54% across trials. This kind of clinical proof helps drive adoption.

Still, physician confidence is key. When provided with a clear definition, 72% of surveyed physicians agreed that DTx would help them better manage patients, even though only 8% initially believed they would have a positive impact in the next 5-10 years.

The high and rising prevalence of type 2 diabetes creates an urgent, large target patient population.

The sheer scale of the chronic disease burden is your biggest tailwind. As of 2025, diabetes affects more than 53 million adults in the United States, representing a 15.8% prevalence rate. That's a huge addressable market. To be fair, about 15 million of those adults are currently undiagnosed, which means screening and early intervention are critical public health goals.

Here's the quick math on the core population: Type 2 diabetes mellitus (T2DM) makes up 90% to 95% of all diabetes cases. Plus, you have the prediabetes group, which is massive-an estimated 97.6 million US adults, or 38% of the adult population, have prediabetes and are at risk of developing T2DM without intervention.

Here is a snapshot of the scale:

Metric (US Adults, 2025 Est.)	Value
Total Adults with Diabetes	Over 53 million
Total Diabetes Prevalence	15.8%
Diagnosed Adults	~38 million
Undiagnosed Adults	~15 million
Adults with Prediabetes	97.6 million

Physician inertia and lack of familiarity with prescribing software remain key adoption hurdles.

Getting physicians to change their established habits is tough. The biggest stated barrier for physicians adopting DTx is the need for education on how to use them, with 63% of doctors citing this as a main hurdle. If your software doesn't integrate seamlessly into their existing electronic health record (EHR) systems, it just adds administrative burden, which is a major contributor to burnout.

Honestly, if onboarding a new digital tool feels like learning a whole new language, many busy clinicians will just skip it. They need to be confident in the evidence, and that education process for a new class of treatment like DTx can take much longer than for a traditional pill.

• Education on use is the main barrier.
• Workflow integration is non-negotiable.
• Tech literacy can slow adoption.

Health equity concerns demand accessible technology and defintely require robust patient support.

The digital revolution risks leaving vulnerable groups behind, and that's a serious social and ethical issue Better Therapeutics, Inc. must address proactively. The digital divide persists in 2025, meaning lack of broadband access and low digital literacy prevent underserved populations from benefiting from tools like remote monitoring. If onboarding takes 14+ days, churn risk rises, especially for those struggling with basic tech access.

The World Health Organization's strategy through 2025 stresses that digital health must support equitable and universal access. For patients facing stigma or with lower income, concerns over data privacy and security can create significant mistrust, making them hesitant to engage with digital health services. You need more than just a good app; you need robust patient support to bridge these gaps and ensure your solution doesn't worsen existing disparities.

Finance: draft 13-week cash view by Friday.

Better Therapeutics, Inc. (BTTX) - PESTLE Analysis: Technological factors

You're building a business on software as medicine, so the tech stack isn't just a feature; it's the entire product. For Better Therapeutics, the core value proposition hinges on the reliable, secure, and scalable delivery of their prescription digital therapeutic (PDT), AspyreRx.

AspyreRx's core mechanism is digitally delivered Cognitive Behavioral Therapy (CBT) for metabolic disease

The whole game for Better Therapeutics centers on AspyreRx, which delivers Cognitive Behavioral Therapy (CBT) via a smartphone app for adults with Type 2 Diabetes (T2D). This isn't just a wellness app; it's an FDA-authorized treatment designed to target the underlying psychological and behavioral drivers of the disease. The clinical proof is compelling: in their pivotal trial, one in two subjects achieved a mean HbA1c reduction of 1.3% after 180 days of use compared to a control group. That's a tangible clinical outcome delivered through software. This digital delivery method is what allows for a self-paced, engaging experience that complements traditional care.

Seamless integration with Electronic Health Records (EHRs) is a critical technical barrier to scalable prescribing

Getting a prescription written is one thing; getting it into the doctor's workflow seamlessly is another. For AspyreRx to move beyond early adopters, integration with the existing Electronic Health Records (EHRs) systems used by prescribing clinicians must be flawless. This technical hurdle dictates prescription volume. While Better Therapeutics announced a partnership with Glooko-a platform used by over 3.4 million people with diabetes across nearly 5,000 clinic locations-to facilitate prescribing and tracking, true scalability requires deep, bidirectional data exchange with the major EHR vendors. If onboarding a new clinic means a two-week IT integration project, your prescription growth curve flattens fast. Honestly, this friction point is where many digital health companies stall out.

Future enhancements will require integrating AI/ML to personalize the therapeutic content and improve engagement

The current version of AspyreRx is a solid foundation, but the next leap in efficacy and patient adherence will come from Artificial Intelligence and Machine Learning (AI/ML). The industry trend is clear: AI-powered personalized medicine tailors treatments based on individual data, which is exactly what CBT needs to stay relevant for a patient over months. Future versions will likely use ML to adjust the therapeutic content delivery frequency or focus based on real-time engagement data or even external biometric inputs. Better Therapeutics has stated their platform uses AI technology for decision support, but the next phase involves using it to drive personalization, which could help push engagement rates-which were at 81% at day 180 in the trial-even higher.

Continuous data security and privacy compliance (HIPAA) is mandatory for handling sensitive patient data

Handling Protected Health Information (PHI) means you live and die by the Health Insurance Portability and Accountability Act (HIPAA). In 2025, the regulatory environment is only getting tighter; we're seeing a shift where previously 'addressable' safeguards are now mandatory, and enforcement is more punitive. For Better Therapeutics, this means every line of code, every cloud server, and every Business Associate Agreement (BAA) must be rock solid. A single breach could lead to fines ranging from $10,000 to $1.5 million per violation, plus the irreparable damage to patient trust. You defintely need Multi-Factor Authentication (MFA) on all access points and end-to-end encryption for all data, both in transit and at rest. This isn't optional; it's the cost of entry for prescription software.

Here's a quick look at where the technology stands against the market realities as of late 2025:

Technical Area	Key Metric/Requirement (2025 Data)	Near-Term Risk/Action
Core Efficacy Data	1.3% mean A1c reduction at 180 days	Sustaining this efficacy across a broader, less-selected patient population.
Scalability/Adoption	Partnership covering over 70 million lives via PBM	Translating PBM coverage into actual, paid prescriptions; EHR integration friction.
Data Security (HIPAA)	Fines up to $1.5 million per violation; MFA mandatory	Ensuring 100% compliance with new mandatory security specifications; audit readiness.
Future Tech	General healthcare AI market growth accelerating	Developing and validating proprietary AI/ML models for personalization without compromising HIPAA.

Finance: draft 13-week cash view by Friday.

Better Therapeutics, Inc. (BTTX) - PESTLE Analysis: Legal factors

You're dealing with a product that lives on a smartphone but treats a serious medical condition, so the legal tightrope you walk is exceptionally thin. The regulatory environment for prescription digital therapeutics (PDTs) is unforgiving, and any misstep in compliance or IP defense can wipe out years of clinical work.

FDA authorization (De Novo) requires ongoing post-market surveillance and performance reporting.

Since Better Therapeutics, Inc. secured its de novo clearance for AspyreRx in July 2023, the clock is ticking on mandatory post-market activities. The Food and Drug Administration (FDA) doesn't just approve a device and walk away; they require systematic monitoring of how the software performs in the real world. This means you must adhere to regulations like 21 CFR Part 803 for Medical Device Reporting (MDR) on adverse events and potentially 21 CFR Part 822 for Section 522 Post-Market Surveillance (PMS) studies if the FDA required them. Honestly, failing to report a serious device-related incident within the required timeframe is a direct regulatory violation, not just a clerical error. The FDA also mandates annual reporting on the status of these postmarket studies, which they publish in the Federal Register.

Strict adherence to HIPAA and other patient data privacy laws is a constant, high-stakes operational requirement.

Handling Protected Health Information (PHI) means HIPAA compliance is non-negotiable, and the rules are getting tougher, not easier, heading into 2025. The Department of Health & Human Services (HHS) proposed significant changes to the HIPAA Security Rule in early 2025, which, if finalized, could impose substantial operational and financial burdens. HHS estimated the industry-wide first-year cost for these proposed changes alone to be around $9 billion. For Better Therapeutics, Inc., this means ensuring that any new AI tools used for analysis or operations have airtight Business Associate Agreements (BAAs) and that disaster recovery plans can restore critical systems within 72 hours, a new proposed benchmark. If onboarding takes 14+ days, churn risk rises, but if data security lapses, the financial and reputational risk is far greater.

The evolving legal landscape for Software as a Medical Device (SaMD) liability needs careful monitoring.

The line between software as a service and a regulated medical product is blurring, creating new liability exposure for SaMD makers. You must watch how courts treat software that causes patient harm under product liability theories, as this area is expected to become more litigious. Globally, the EU's New Product Liability Directive, enacted in late 2024, explicitly broadens liability to include digital products and shifts some burdens of proof onto the manufacturer, which often sets the tone for US regulatory thinking. A pivotal question in 2025 is whether AI systems are classified as products or services, as that classification dictates how liability is assigned and safety standards are enforced.

Securing and defending intellectual property for the novel therapeutic mechanism is crucial for long-term defensibility.

Your core value is locked in your proprietary cognitive behavioral therapy platform. Defending that innovation against infringement is paramount. Nationally, patent litigation is showing a modest upward trend in 2025, with the Eastern District of Texas, Western District of Texas, and the District of Delaware being the busiest venues. Furthermore, the legal framework for obviousness in patent claims is shifting; the Federal Circuit is moving toward a more flexible approach, overturning older tests like the Rosen-Durling test for design patents. You need to ensure your utility and design patents are robust under these evolving standards, especially with proposed legislation like the Patent Eligibility Restoration Act (PERA) still being debated to clarify subject matter eligibility.

Here's a quick look at the key legal compliance vectors:

Legal Factor	Primary Regulatory/Legal Concern	Key 2025 Data Point / Risk Metric
FDA Post-Market	Timely reporting of adverse events (MDR) and study completion.	Mandatory reporting under 21 CFR Part 803.
Data Privacy (HIPAA)	Safeguarding ePHI; compliance with proposed Security Rule changes.	Estimated industry-wide first-year cost for proposed 2025 rule changes: $9 billion.
SaMD Liability	Product vs. service classification; manufacturer burden of proof in claims.	EU Directive broadens liability to digital products (enacted Dec 2024).
Intellectual Property	Defending patents against obviousness challenges; patent eligibility clarity.	Top 3 US patent litigation districts in 2025: EDTX, WDTX, D. Del.

Legal: Draft a memo by next Wednesday detailing the specific Section 522 study requirements tied to the AspyreRx clearance and map them against current internal data collection capabilities.

Better Therapeutics, Inc. (BTTX) - PESTLE Analysis: Environmental factors

You're looking at the Environmental factor for Better Therapeutics, Inc. ($\text{BTTX}$), and the good news is that as a prescription digital therapeutic ($\text{PDT}$) company, your direct footprint is minimal compared to, say, a traditional pharmaceutical manufacturer. This is the core of your environmental story: you are selling software, not physical goods that require complex supply chains or heavy manufacturing waste.

Minimal Direct Environmental Impact from Operations

Because $\text{BTTX}$'s product, $\text{AspyreRx}$, is software-only, the direct environmental impact from product creation is negligible. You aren't dealing with chemical waste or large-scale physical production. Your primary direct impacts come from office energy use, data center energy consumption for cloud hosting, and employee travel. Honestly, for a company whose securities were undergoing delisting review in early 2024, the focus was likely on cash preservation, but the underlying environmental principle remains: keep the digital infrastructure lean.

Still, every digital operation has a footprint. Here's a quick look at the operational considerations:

• Data Center Energy: Reliance on cloud providers whose own sustainability commitments matter.
• Office Energy: Energy efficiency in your San Francisco base of operations.
• Waste Management: Minimizing paper use in administrative and clinical trial processes.

The global digital therapeutics market is projected to be worth around $\text{\$17.6}$ billion in 2025, according to one estimate, showing massive growth in the sector you inhabit, which means even small operational efficiencies scale up in importance.

Indirect Sustainability Through Product Use

This is where your real environmental leverage lies. Your product is designed to change behavior for cardiometabolic diseases like Type 2 Diabetes, which means it directly supports sustainability by reducing the need for in-person, travel-intensive clinical visits. Think about the reduction in carbon emissions from patients driving to and from appointments, or even the energy used by physical clinics.

The potential for this indirect benefit is huge, especially as the $\text{DTx}$ sector continues to mature; investments in $\text{DTx}$ were expected to surge by $\text{26.7\%}$ year over year between 2020-2025. If $\text{BTTX}$'s solution achieves broad adoption, the cumulative reduction in patient travel could be substantial. What this estimate hides, however, is the actual patient adherence rate needed to displace a physical visit.

The positive environmental contribution is tied to:

• Reducing patient travel for routine check-ins.
• Potentially reducing unnecessary physical diagnostic testing.
• Enabling remote monitoring, which is inherently less resource-intensive.

Electronic Waste and Device Compatibility

Since your product runs on consumer devices-smartphones and tablets-you must prioritize energy efficiency and device compatibility to reduce electronic waste generation. A poorly optimized app drains a user's battery faster, indirectly contributing to the device's overall energy consumption and potentially shortening its useful life, pushing users toward earlier replacement.

Design must focus on lightweight code and efficient data transfer. For instance, if your application requires constant, high-bandwidth data streaming, the environmental cost shifts to the network infrastructure. Conversely, if you can streamline data synchronization, you help mitigate this.

Here is a comparison of potential impacts:

Factor	Direct Impact (Low for $\text{BTTX}$)	Indirect Impact (High Potential for $\text{BTTX}$)
Manufacturing Waste	Near zero (Software only)	N/A
Patient Travel Emissions	N/A	Significant reduction potential via remote care
Device Lifespan/E-Waste	Low (Efficient coding helps)	Moderate (Battery drain from inefficient software)
Data Center Energy Use	Low to Moderate (Cloud dependent)	N/A

ESG Profile Weighting

To be defintely clear, $\text{BTTX}$'s overall Environmental, Social, and Governance ($\text{ESG}$) profile is heavily weighted toward the 'Social' component. The entire premise of a $\text{PDT}$ for chronic disease management is improving patient health access and outcomes-that's a massive 'S' factor win. The 'E' factor is secondary and mostly about responsible digital operation.

You should track metrics that reflect this weighting. While I don't have $\text{BTTX}$'s specific 2025 $\text{ESG}$ data, a peer in the digital health space might report on things like:

• Percentage reduction in paper records converted to electronic systems.
• Estimated patient travel miles avoided due to remote therapy.
• Energy efficiency benchmarks for the application per active user session.

Finance: draft 13-week cash view by Friday.